Conferences
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.
The German biotech has been forced into insolvency and NASDAQ suspension.
The company hopes the drug will become the standard of care rescue treatment in asthma.
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
The sector is continuing to show resilience despite financial and market challenges.
The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.
The UK giant is forecasting peak sales of $5bn plus
Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.
Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.
CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.
The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.
Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.
Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.
Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.
CEO Daniel O’Day and EVP-research Flavius Martin highlighted Gilead’s inflammation R&D and dealmaking focus at the recent J.P. Morgan meeting.
The year is off to a good start for the Japanese pharma with back-to-back approvals in the US. CEO Ken Keller talked to Scrip about some recent setbacks and looking ahead.
Continuing to grow Nuplazid and Daybue are top priorities along with pipeline and business development, Catherine Owen Adams told Scrip.